Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Devin Incerti"'
Autor:
Sara Y Tartof, Lei Qian, Liyan Liu, Devin Incerti, Jacek Skarbinski, Laura B Amsden, Bradley K Ackerson, Vennis Hong, Bruce H Fireman, Vincent M Yau, Heidi Fischer, Sally F Shaw
Publikováno v:
BMJ Open, Vol 12, Iss 10 (2022)
Objectives Assess the association between tocilizumab administration and clinical outcomes among mechanically ventilated patients with COVID-19 pneumonia.Design Retrospective cohort study.Setting Large integrated health system with 9 million members
Externí odkaz:
https://doaj.org/article/bbfd3cd482434b3584ba78b0efecad85
Autor:
Shemra Rizzo, Xiao Li, Devin Incerti, Lisa Lindsay, Vincent Yau, Dan Keebler, Jenny Chia, Larry Tsai
Publikováno v:
BMJ Open, Vol 11, Iss 4 (2021)
Objectives To develop a prognostic model to identify and quantify risk factors for mortality among patients admitted to the hospital with COVID-19.Design Retrospective cohort study. Patients were randomly assigned to either training (80%) or test (20
Externí odkaz:
https://doaj.org/article/d44cb3fa5ba04dcb8bffe49d9d495b26
Autor:
Devin Incerti, John Browne, Caroline Huber, Christine L. Baker, Geoff Makinson, Amir Goren, Richard Willke, Warren Stevens
Publikováno v:
BMC Health Services Research, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background Although there has been growing attention to the measurement of unmet need, which is the overall epidemiological burden of disease, current measures ignore the burden that could be eliminated from technological advances or more ef
Externí odkaz:
https://doaj.org/article/6a8811dec20541adad9f9fcd06044c4a
Autor:
Devin Incerti, Nicholas Summers, Thanh G. N. Ton, Audra Boscoe, Anil Chandraker, Warren Stevens
Publikováno v:
MDM Policy & Practice, Vol 3 (2018)
Background. Although delayed graft function (DGF) is associated with an increased risk of acute rejection and decreased graft survival, there are no estimates of the long-term or lifetime health burden of DGF. Objectives. To estimate the long-term an
Externí odkaz:
https://doaj.org/article/0218244c03614937b279a55c2dc43765
Autor:
Sarah P. Huepenbecker, Jason D. Wright, Mary K. Downer, Devin Incerti, Patricia Luhn, Ignacio Dolado, Lydie Bastiere-Truchot, Yvonne G. Lin, John K. Chan, Larissa A. Meyer
Publikováno v:
Obstetrics & Gynecology. 140:758-767
Autor:
Xavier G.L.V. Pouwels, Christopher J. Sampson, Renée J.G. Arnold, Manthan D. Janodia, Raymond Henderson, Mark Lamotte, Warren Cowell, John Borrill, Christine Huttin, Nayanabhirama Udupa, Cynthia L. Gong, Lee Shee Lan, Lance Brannman, Devin Incerti, K.V. Ramanath, Celine Pribil, Oleksandra Oleshchuk, Olena Pokotylo, Wendelin Schramm, Mark Nuijten
Publikováno v:
Value in health, 25(4), 473-479. Elsevier
Objectives: Health economic (HE) models are routinely used to support health policy and resource allocation decisions but are often considered “black boxes” that may be prone to error and bias. Open source models (OSMs) have been advocated to inc
Publikováno v:
Pharmaceutical statisticsREFERENCES.
While randomized controlled trials (RCTs) are the gold standard for estimating treatment effects in medical research, there is increasing use of and interest in using real-world data for drug development. One such use case is the construction of exte
Publikováno v:
Pharmaceutical statisticsREFERENCES.
Time-to-event data such as time to death are broadly used in medical research and drug development to understand the efficacy of a therapeutic. For time-to-event data, right censoring (data only observed up to a certain point of time) is common and e
Autor:
Thibaut Sanglier, D. Tesarowski, Patricia Luhn, Eleonora Restuccia, Anita Fung, Carlos Flores, Preet K. Dhillon, Devin Incerti, Vincent Antao
Publikováno v:
Cancer Research. 81:PS10-20
OBJECTIVES Over the last decade, new treatment options have transformed the standard of care for patients (pts) with HER2-positive EBC and the treatment landscape continues to evolve. The primary objectives of our study were (1) to describe and compa
Autor:
Devin Incerti, Krishnan Ramaswamy, Desi Peneva, Gregory Smith, Anshu Shrestha, Warren Stevens
Publikováno v:
Health Economics. 29:580-590
Cost-effectiveness is traditionally treated as a static estimate driven by clinical trial efficacy and drug price at launch. Prior studies suggest that cost-effectiveness varies over the drug's lifetime. We examined the impact of "learning by doing,"